

Light AI Reports Financial Results for Q1 2025

Vancouver, B.C. – May 15, 2025 – Light Al Inc. ("Light Al" or the "Company") (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence ("AI") health diagnostic and wellness solutions, today announced its financial and operating results for its first quarter of 2025 representing the three months ended March 31, 2025. Financial information is reported in Canadian dollars ("\$") unless otherwise stated and in accordance with International Financial Reporting Standards ("IFRS").

Financial and Operating Results Summary for Q1 2025

The Company is currently in the development stage of its software technology offering which is anticipated to be completed with related commercialization commencing in Q3 2025. During the three months ended March 31, 2025, the Company had total operating expenses, exclusive of interest, depreciation and share based payments, of approximately \$4.2 million compared to approximately \$1.4 million in the three months ended March 31, 2024 with the increase primarily attributable to the Company's continued investment in product development with total research and development expenses of approximately \$1.2 million in Q1 2025 compared to approximately \$919,000 in the prior year period in addition to marketing and investor relations activities.

The Company had cash of \$11.9 million as of March 31, 2025 compared to \$15.2 million as of December 31, 2025. On January 8, 2025, the Company closed the second of two tranches of the Offering by issuing 2,757,000 units of the Company at \$0.55 per unit for aggregate gross proceeds of \$1,516,350. The Company had Adjusted Working Capital of \$12.6 million as of March 31, 2025 compared to \$14.6 million as of December 31, 2025.

"Light AI has made strong progress throughout the first quarter of 2025, inclusive of going public with the completion of related equity financings totaling \$18.5 million and strengthening our leadership team with the appointments of Anthony Schaller as President and CTO, John Tse as VP Commercial Development and George Reznik as CFO," stated Peter Whitehead, CEO of Light AI. "We are committed to commercializing the Company's AI oriented health and wellness software application in Q3 2025 to address various medical conditions including Strep A, COVID19 and Conjunctivitis (pink eye) to capitalize on our sizable market opportunity leveraging Light Al's first mover advantage with our innovative, patented and disruptive technology."

Financial Statements and Management Discussion & Analysis

Please see the Company's consolidated financial statements ("Financial Statements") and related Management's Discussion & Analysis ("MD&A") for more details. The Financial Statements for the three months ended March 31, 2025, and related MD&A have been reviewed and approved by the Company's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed on SEDAR+ at www.sedarplus.ca and is also available on the Company's website at www.light.ai.

Non-IFRS and Other Financial Measures

Current Assets

This press release refers to the following non-IFRS measures: "Adjusted Working Capital" is comprised as current assets less current liabilities.

Management believes Adjusted Working Capital is a useful indicator for investors, and is used by management, for evaluating the operating liquidity to the Company. See "Adjusted Working Capital Reconciliation" for a quantitative reconciliation of Adjusted Working Capital to the most directly comparable financial measure. Such non-IFRS measures and non-IFRS ratio do not have a standardized meaning under

Adjusted Working Capital Reconciliation

IFRS and may not be comparable to a similar measure disclosed by other issuers.

December 31, 2024

Less: Current Liabilities (2,352,273)(2,481,677)**Adjusted Working Capital** \$12,618,241 \$14,644,568

March 31, 2025

\$14,970,514

\$17,126,245

Light AI Inc. is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies Al algorithms to

About Light Al Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: 0HCFF)

COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind-its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective diagnostic tools designed to address critical healthcare challenges. In pre-FDA validation studies, Light Al's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a

Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600

smartphone images-starting with images of Strep A and anticipated expansion with

million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding \$1 trillion annually. Light Al's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light Al's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light Al's vision is to combine the smartphone with Al in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes. Light Al's commercial launch of its consumer-facing Wellness App initial offering is anticipated to be available in North America in Q3 2025. ON BEHALF OF THE COMPANY "George Reznik" **George Reznik**

looking, and which reflect current estimates, expectations and projections about future

affect any of the Company's forward-looking statements, please refer to the Company's annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at www.sedarplus.ca). Light AI disclaims any intention or obligation to update or revise any forward-looking information contained in this news release, whether as a result of new

information included in this news release is expressly qualified in its entirety by this

information, future events or otherwise, unless required by applicable law. The forward-looking

Telephone: 604-307-6800 Email: <u>greznik@light.ai</u>

For more information, please contact the Company at investors@light.ai or visit https://light.ai/. **Media Contact:** Sarah Mawji-Walker

Chief Financial Officer

Website: https://light.ai/ LinkedIn: LinkedIn/Company/Light Al X (Formerly Twitter): @lightaihealth

Venture Strategies

Forward-Looking Information:

sarah@venturestrategies.com

This news release includes information, statements, beliefs and opinions which are forward-

cautionary statement.

events, including, but not limited to, the Company's research and development and commercialization initiatives, the anticipated inflection of the business, the Company's financial and operational performance and outlook and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," "intend," "positioned," risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may